Evaluation of the effect of esketamine hydrochloride applied in pediatric urological operation anesthesia

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200055845

Enrollment

Unknown

Registered

2022-01-20

Start date

2022-02-01

Completion date

Unknown

Last updated

2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Concealed Penis

Interventions

Control group (group C):Intravenous injection of 0.01mg/kg penehyclidine hydrochloride, 0.4ug/kg sufentanil, 2.0mg/kg propofol, 0.15mg/kg cis-atracurium

Esketamine group (group E):Intravenous injection of penehyclidine hydrochloride 0.01mg/kg, 0.5mg/kg esketamine (Jiangsu Hengrui Pharmaceutical Co., Ltd., specification is 2ml: 50 mg), 0.4ug/kg sufenta

Eligibility

Sex/Gender

All

Age

6 Years to 14 Years

Inclusion criteria

Inclusion criteria: A total of 60 children with elective urological surgery, aged 6 to 14 years old, with ASA grades I-II

Exclusion criteria

Exclusion criteria: 1. Those whose family members refuse to participate; 2. Those who have intellectual disability and developmental delay; 3. Those who have contraindications to the use of esketamine; 4. Those who have other vital organ diseases.

Design outcomes

Primary

Measure	Time frame
blood pressure;degree of blood oxygen saturation;heart rate;Breathing rate;Blood oxygen saturation;Drug dosage;Length of operation;Duration of anesthesia;PAED score;FLACC score;VAS score;	—

Countries

China

Contacts

Public ContactXue Rui

People's Hospital of Shiyan City

xuerui1106@126.com+86 13476167178

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026